Search research articles
Contact Us
Filters
Showing results (151-160 of 181) with videos related to
Page
of 19
Sort By:
NPJ Precision Oncology
|
February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
The Lancet. Oncology
|
June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Research Square
|
August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
JAMA Oncology
|
November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
Shubham Pant, Jia Fan, Do-Youn Oh, et al.
BMJ Oncology
|
January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
Chad Tang, Genevieve P Hartley, Coline Couillault, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 181) with videos related to
Sort By:
Page
of 19
NPJ Precision Oncology
|
February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer
|
January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
The Lancet. Oncology
|
June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Research Square
|
August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
JAMA Oncology
|
November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01
Shubham Pant, Jia Fan, Do-Youn Oh, et al.
BMJ Oncology
|
January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
Chad Tang, Genevieve P Hartley, Coline Couillault, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Page
of 19